@article{44166d66c7304c52b988f0b97ee80522,
title = "Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study",
abstract = "Purpose Rituximab (Rit) therapy added to involved-field radiation therapy (RT) has been proposed as an effective treatment for stage I-II follicular lymphoma (FL). The results of an observational multicenter study on the Rit-RT combination in limited-stage FL are here reported. Methods and Materials Data have been collected from 2 consecutive cohorts of 94 patients with stage I-II FL treated between 1985 and 2011 at 5 Italian institutions. All patients had grade 1-3a FL, a median age of 54 years (range: 25-82). The first 51 patients received RT alone (control group), while the subsequent series of 43 patients received 4 rituximab courses (375 mg/m2, days 1, 8, 15, 22) before RT (Rit-RT). Molecular disease was evaluated by nested bcl-2/IgH PCR or clonal IgH rearrangement was available in 33 Rit-RT patients. Results At a median follow-up of 10.9 years (range: 1.8-22.9), the 10-year progression-free survival (PFS) and overall survival (OS) projections for the whole cohort were 57% and 87.5%, respectively. The 10-year PFS was significantly longer (P<.05) in the Rit-RT group (64.6%) compared to RT alone (50.7%), whereas the 10-year OS projections were not significantly different. On bivariate analysis controlling for stage, there was only a trend toward improved PFS for Rit-RT (HR, 0.55; P=.081). Follicular lymphoma international prognostic index and age were associated with OS but not with PFS on Cox regression analysis. Bone marrow molecular analysis showing PCR positivity at diagnosis was strongly associated with relapse risk upon univariate and multivariate analysis. Conclusions This multicenter observational study suggests a potential benefit of adding rituximab to radiation therapy for stage I-II FL. The results of the currently ongoing randomized studies are required to confirm these results. The study underlines the importance of molecular disease monitoring also for patient with limited-stage disease. {\textcopyright} 2016 Elsevier Inc. All rights reserved.",
keywords = "Diagnosis, Multivariant analysis, Oncology, Radiotherapy, Regression analysis, Risk assessment, Cox regression analysis, Disease monitoring, Follicular lymphoma, Involved-field radiation therapy, Methods and materials, Multi variate analysis, Observational study, Progression free survival, Patient treatment, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine, antineoplastic agent, adult, age, aged, Article, cancer radiotherapy, cancer recurrence, cohort analysis, controlled study, female, follicular lymphoma, Follicular Lymphoma International Prognostic Index, follow up, human, hypothyroidism, involved field radiation therapy, large cell lymphoma, lymphocytopenia, major clinical study, male, molecular probe, mucosa inflammation, multicenter study, neutropenia, observational study, overall survival, polymerase chain reaction, priority journal, progression free survival, radiation field, radiation injury, smoking, very elderly, xerostomia, bone marrow, chemoradiotherapy, clinical trial, disease free survival, Lymphoma, Follicular, middle aged, mortality, pathology, procedures, retrospective study, survival analysis, time factor, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Bone Marrow, Chemoradiotherapy, Disease-Free Survival, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Rituximab, Survival Analysis, Time Factors",
author = "Marco Ruella and Filippi, {Andrea Riccardo} and Riccardo Bruna and {Di Russo}, A. and M. Magni and D. Caracciolo and R. Passera and P. Matteucci and {Di Nicola}, M. and P. Corradini and Guido Parvis and G. Gini and A. Olivieri and Marco Ladetto and Umberto Ricardi and C. Tarella and L. Devizzi",
note = "Cited By :2 Export Date: 30 March 2017 CODEN: IOBPD Correspondence Address: Tarella, C.; Division of Haematology and Cell Therapy, Mauriziano Hospital, University of TorinoItaly Chemicals/CAS: cyclophosphamide, 50-18-0; doxorubicin, 23214-92-8, 25316-40-9; prednisone, 53-03-2; rituximab, 174722-31-7; vincristine, 57-22-7; Antineoplastic Agents; Rituximab Tradenames: mabthera, f hoffmannla roche, Switzerland Manufacturers: f hoffmannla roche, Switzerland References: Howlader, N.N.A., Krapcho, M., Garshell, J., SEER Cancer Statistics Review, 1975-2011, , http://seercancergov/csr/1975_2011/2014, Accessed July 1, 2015; Friedberg, J.W., Byrtek, M., Link, B.K., Effectiveness of first-line management strategies for stage i follicular lymphoma: Analysis of the National LymphoCare Study (2012) J Clin Oncol, 30, pp. 3368-3375; Zelenetz, A.D., Abramson, J.S., Advani, R.H., NCCN clinical practice guidelines in oncology: Non-Hodgkin's lymphomas (2010) J Natl Compr Canc Netw, 8, pp. 288-334; Ghielmini, M., Vitolo, U., Kimby, E., ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL) (2013) Ann Oncol, 24, pp. 561-576; Zinzani, P.L., Marchetti, M., Billio, A., SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma (2013) Am J Hematol, 88, pp. 185-192; Ahmed, N., Owen, T.E., Rubinger, M., Early stage WHO grade i and II follicular lymphoma treated with radiation therapy alone (2013) PLoS One, 8, p. e65156; Mac Manus, M.P., Hoppe, R.T., Is radiotherapy curative for stage i and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University (1996) J Clin Oncol, 14, pp. 1282-1290; Wilder, R.B., Jones, D., Tucker, S.L., Long-term results with radiotherapy for stage I-II follicular lymphomas (2001) Int J Radiat Oncol Biol Phys, 51, pp. 1219-1227; Guadagnolo, B.A., Li, S., Neuberg, D., Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy (2006) Int J Radiat Oncol Biol Phys, 64, pp. 928-934; Lowry, L., Smith, P., Qian, W., Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial (2011) Radiother Oncol, 100, pp. 86-92; Monfardini, S., Banfi, A., Bonadonna, G., Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma (1980) Int J Radiat Oncol Biol Phys, 6, pp. 125-134; Stuschke, M., Hoederath, A., Sack, H., Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: Results of a prospective multicenter study. Study Group NHL-fruhe Stadien (1997) Cancer, 80, pp. 2273-2284; Nissen, N.I., Ersboll, J., Hansen, H.S., A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas (1983) Cancer, 52, pp. 1-7; Yahalom, J., Varsos, G., Fuks, Z., Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage i low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study (1993) Cancer, 71, pp. 2342-2350; McLaughlin, P., Fuller, L., Redman, J., Stage I-II low-grade lymphomas: A prospective trial of combination chemotherapy and radiotherapy (1991) Ann Oncol, 2, pp. 137-140; Kelsey, S.M., Newland, A.C., Hudson, G.V., A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma (1994) Med Oncol, 11, pp. 19-25; Feuring-Buske, M., Kneba, M., Unterhalt, M., IDEC-C2B8 (rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: Results of a phase-II study of the German Low-Grade Lymphoma Study Group (2000) Ann Hematol, 79, pp. 493-500; Freedman, A., Follicular lymphoma: 2014 update on diagnosis and management (2014) Am J Hematol, 89, pp. 429-436; Colombat, P., Salles, G., Brousse, N., Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation (2001) Blood, 97, pp. 101-106; Rambaldi, A., Lazzari, M., Manzoni, C., Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma (2002) Blood, 99, pp. 856-862; Ladetto, M., Magni, M., Pagliano, G., Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma (2006) Biol Blood Marrow Transplant, 12, pp. 1270-1276; Skvortsova, I., Skvortsov, S., Popper, B.A., Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - Independent mechanisms (2006) J Radiat Res (Tokyo), 47, pp. 183-196; Skvortsova, I., Popper, B.A., Skvortsov, S., Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells (2005) J Radiat Res (Tokyo), 46, pp. 241-248; Cheson, B.D., Horning, S.J., Coiffier, B., Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group (1999) J Clin Oncol, 17, p. 1244; Ladetto, M., Lobetti-Bodoni, C., Mantoan, B., Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program (2013) Blood, 122, pp. 3759-3766; Seymour, J.F., Pro, B., Fuller, L.M., Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma (2003) J Clin Oncol, 21, pp. 2115-2122; Maloney, D.G., Grillo-Lopez, A.J., Bodkin, D.J., IDEC-C2B8: Results of a phase i multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma (1997) J Clin Oncol, 15, pp. 3266-3274; McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program (1998) J Clin Oncol, 16, pp. 2825-2833; Ardeshna, K.M., Qian, W., Smith, P., Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial (2014) Lancet Oncol, 15, pp. 424-435; Wilen, C.B., Wang, J., Tilton, J.C., Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases (2011) PLoS Pathog, 7, p. e1002020; Casulo, C., Byrtek, M., Dawson, K.L., Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study (2015) J Clin Oncol, 33, pp. 2516-2522; Maurer, M.J., Ghesquieres, H., Ansell, S.M., Event-free survival at 12 months (EFS12) from diagnosis is a robust endpoint for disease-related survival in patients with follicular lymphoma in the immunochemotherapy era [abstract] (2014) Blood, 124, p. 1664; Hiddemann, W., Cheson, B.D., How we manage follicular lymphoma (2014) Leukemia, 28, pp. 1388-1395; Corradini, P., Astolfi, M., Cherasco, C., Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting (1997) Blood, 89, pp. 724-731; Hoskin, P.J., Kirkwood, A.A., Popova, B., 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): A randomised phase 3 non-inferiority trial (2014) Lancet Oncol, 15, pp. 457-463; Kahl, B.S., Hong, F., Williams, M.E., Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern cooperative oncology group protocol e4402 (2014) J Clin Oncol, 32, pp. 3096-3102; Herfarth, K., Engelhard, M., Borchmann, P., Treatment of early stage nodal follicular lymphoma using involved-field radiation therapy and rituximab: Preliminary results of the Mir Trial (phase II study of the German Low Grade Lymphoma Study Group (GLSG)) [abstract] (2012) Blood, 120, p. 1634; Prica, A., Chan, K., Cheung, M., Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis (2015) Cancer, 121, pp. 2637-2645",
year = "2016",
doi = "10.1016/j.ijrobp.2015.12.019",
language = "English",
volume = "94",
pages = "783--791",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",
}